Back to Journal

SM Journal of Pharmacology and Therapeutics

New Malic Enzyme 1 Inhibitor Design Using Fragmental-Based Virtual Screening and Molecular Dynamic Simulation

[ ISSN : 2574-2396 ]

Abstract
Details

Received: 06-Dec-2018

Accepted: 18-Dec-2018

Published: 20-Dec-2018

Fatemeh Ramezani

Faculty of Medicine, Iran University of Medical Sciences, Iran

Corresponding Author:

Fatemeh Ramezani, Physiology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran, Email: ramezani.f@iums.ac.ir

Keywords

Malic enzyme 1; Fragment based drug discovery; Cancer; Screening

Abstract

Cancer is a deadly disease with a high mortality rate and the most advanced oncology centers of the world are trying to find solutions for it. The most advanced method used for treating cancer is based on the change of metabolism in cancerous cells, namely, the rise of enzymes participating in metabolism and the supply of energy to the cell. Malic enzyme 1 regulates the redox equilibrium, cellular energy, and the synthesis of biomolecules by conversion of a TCA cycle intermediate, malic acid, into NADPH and pyruvic acid. Thus, Malic enzyme 1 seems like a capable asset in the treatment of cancer and its inhibitors can be used to hinder the growth of the cancerous cell. In the present study, we have been using Fragment-based method of drug discovery using molecular dynamic simulation and molecular docking in order to create an inhibitor for malic enzyme 1. After testing roughly ninety thousand pieces of interaction with the binding site of NAD (P) with regard to the type of interactions, binding energy, and the compound orientation on the site, finally, combination 1f was selected as the best inhibitor.

Citation

Ramezani F. New Malic Enzyme 1 Inhibitor Design Using Fragmental-Based Virtual Screening and Molecular Dynamic Simulation. SM J Pharmac Ther. 2018; 4(1): 1020s1.